This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of -4.76% and 48.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Upgraded to Buy: Here's Why
by Zacks Equity Research
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.
BEAM Down Despite Positive Initial Data From Genetic Disorder Study
by Zacks Equity Research
Beam Therapeutics posts positive initial data from a phase I/II study investigating BEAM-302 for treating alpha-1 antitrypsin deficiency.
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
by Zacks Equity Research
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 25.30% and 293.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -116.67% and 0.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Meets Q4 Earnings Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 0% and 4.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Loses -25.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
by Zacks Equity Research
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)
by Zacks Equity Research
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
by Zacks Equity Research
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 27.55% and 38.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 68.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 67.2% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.